Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 4
Iron infusion for people with aortic stenosis having valve replacement
Tests ferric carboxymaltose in people with aortic stenosis and low iron.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Rotterdam, NetherlandsSee the site
- Trial code
- Registry title
- Iron Infusion in Elderly Patients undergoing Transcatheter Aortic Valve Implantation (IRON TAVI) Trial
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 378 people, planned
- Started
- 15 Jan 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 65 or older with severe aortic stenosis and iron deficiency who had a successful TAVI. TAVI is a valve replacement done through a tube in a blood vessel. The trial tests iron given into a vein (ferric carboxymaltose).
- Age
- 65 years or older (the record also lists a minimum age of 18 Years).
- Sex
- All sexes can join.
- Disease stage
- Severe aortic stenosis (narrowed heart valve), with a successful TAVI already done.
- Earlier treatment
- Must have had a successful TAVI. Cannot join after erythropoietin, iron by vein or mouth, or a blood transfusion in the previous 3 months, or if these are planned within the next 6 months.
- Biomarker or test result
- Iron deficiency: serum iron ≤13 μmol/L and/or transferrin saturation ≤20%. Ferritin must not be > 400 ug/L. Hemoglobin must not be <5.6 mmol/L or <9 g/dL, nor >8.7 mmol/L or >14 g/dL in men and >8.1 mmol/L or >13 g/dL in women.
Main reasons for not taking part
- Infection that needs antibiotics, or allergy to iFCM
- Pregnancy
- Anaemia from other causes, such as blood or bone marrow disease, active cancer or ongoing bleeding
- Chronic liver disease, or liver tests above three times the upper limit of normal
- Dialysis (past, current or planned within 6 months), eGFR <15 mL/min, or past iron overload
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patient age ≥ 65 years
- Patients with severe aortic stenosis and iron deficiency undergoing successful TAVI
- Iron deficiency defined as serum iron ≤13 μmol/L and/or transferrin saturation ≤20%
- Ability to perform assessment of quality of life (questionnaire assessment), exercise capacity (6-minute walk test) and cognitive function assessment (questionnaire assessment)
- Signed Informed Consent
Who cannot take part
- Renal dialysis (previous, current, or planned within the next 6 months) or MDRD/CKD-EPI estimated glomerular filtration rate <15 mL/min
- History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 3 months and/or such therapy planned within next 6 months
- Clinically apparent infection requiring antibiotic treatment
- Known hypersensitivity to iFCM or to any of its excipients
- Study subject participation in another TAVI related clinical study in which the primary endpoint includes mortality, hospitalization for heart failure and/or quality of life assessment
- Anaemia due to known reasons other than ID and/or anticipated non-response to iron-supplementation (e.g. hemogobinopathy, bone marow disease, active cancer, unresolved active bleeding)
- History of iron overload
- Hemoglobin <5.6 mmol/L or <9 g/dL
- Hemoglobin >8.7 mmol/L or >14 g/dL in men and >8.1 mmol/L or >13 g/dL in women
- Chronic liver disease (including active hepatitis) and/or screening alanine transaminase or aspartate transaminase above three times the upper limit of the normal range
- Contra-indication for transfemoral TAVI
- Pregnancy
- Ferritin > 400 ug/L
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To determine whether intravenous iron (ferric carboxymaltose) would improve Quality of life and Exercise Capacity in patients with severe Aortic Stenosis and Iron Deficiency undergoing TAVI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Iron Infusion in Elderly Patients undergoing Transcatheter Aortic Valve Implantation (IRON TAVI) Trial
- Plain-language title
- Iron infusion for people with aortic stenosis having valve replacementGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2026